Sonendo, Inc. (SONX)
USD 1.15
(-14.81%)
USD 1.15
(-14.81%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -54.76 Million USD | 9.49% |
| 2022 | -51 Million USD | -31.84% |
| 2021 | -41.28 Million USD | -11.19% |
| 2020 | -39.13 Million USD | 6.5% |
| 2019 | -43.46 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -9.81 Million USD | -3.87% |
| 2024 Q2 | -6.31 Million USD | 35.45% |
| 2023 Q1 | -14.81 Million USD | -0.35% |
| 2023 FY | - USD | 9.49% |
| 2023 Q4 | -9.4 Million USD | 41.54% |
| 2023 Q2 | -16.11 Million USD | -8.76% |
| 2023 Q3 | -16.09 Million USD | 0.1% |
| 2022 Q4 | -14.76 Million USD | -6.32% |
| 2022 Q3 | -13.88 Million USD | -2.05% |
| 2022 Q2 | -13.6 Million USD | 1.93% |
| 2022 Q1 | -13.87 Million USD | -4.17% |
| 2022 FY | - USD | -31.84% |
| 2021 Q1 | -9.05 Million USD | 14.47% |
| 2021 FY | - USD | -11.19% |
| 2021 Q4 | -13.31 Million USD | -28.97% |
| 2021 Q3 | -10.32 Million USD | -12.43% |
| 2021 Q2 | -9.18 Million USD | -1.39% |
| 2020 Q2 | -10.47 Million USD | 0.0% |
| 2020 Q1 | -10.47 Million USD | 0.0% |
| 2020 FY | - USD | 6.5% |
| 2020 Q4 | -10.59 Million USD | -22.41% |
| 2020 Q3 | -8.65 Million USD | 17.35% |
| 2019 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acutus Medical, Inc. | -13.48 Million USD | -306.08% |
| Biotricity, Inc. | -8.82 Million USD | -520.371% |
| Cell MedX Corp. | - USD | Infinity% |
| Dynatronics Corporation | -976 Thousand USD | -5511.429% |
| Nemaura Medical Inc. | -7.28 Million USD | -651.579% |
| PetVivo Holdings, Inc. | -10.49 Million USD | -421.874% |
| RetinalGenix Technologies Inc. | -2.08 Million USD | -2524.309% |
| Telesis Bio, Inc. | -40.49 Million USD | -35.253% |
| Talis Biomedical Corporation | -66.04 Million USD | 17.075% |
| Viveve Medical, Inc. | -20.61 Million USD | -165.645% |